Ruxolitinib for rheumatic disease-associated macrophage activation syndrome in children: a retrospective cohort study. (PubMed, Front Immunol) - Sep 3, 2026 - "By week 8, the median prednisone-equivalent dose decreased from 4 mg/kg/day to 0.4 mg/kg/day, and all patients successfully discontinued glucocorticoids by week 48 while maintaining remission. Ruxolitinib-based therapy was associated with sustained disease control and a significant glucocorticoid-sparing effect in pediatric RD-MAS. These findings support that ruxolitinib may serve as a promising steroid-sparing strategy with favorable efficacy and safety for pediatric RD-MAS, although larger prospective studies are warranted."
Journal • Retrospective data • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Pediatrics • Rheumatology • Systemic Lupus Erythematosus
|
|
Jun Yang; Mengmeng Zhang; Tingyan He; Xiaona Zhu
|